MedTrace Logo

Phase II Study of Pazopanib and Topotecan in Cervical Cancer

NCT02348398 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-08-16

No results posted yet for this study

Summary

The goal of this clinical research study is to learn if the combination of topotecan and pazopanib can help to control recurrent cervical cancer. The safety of the study drug combination will also be studied.

Conditions

Interventions

DRUG

Pazopanib

600 mg by mouth daily in a 28 day cycle.

DRUG

Topotecan

0.25 mg by mouth daily for 21 days of a 28 day cycle.

BEHAVIORAL

Phone Call

During follow up if disease gets worse, participant called by study staff every 3 months. Each call should last about 5 minutes.

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Michael M. Frumovitz, MD, MPH · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2019-08-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02348398 on ClinicalTrials.gov